A federal health official’s ruling has cleared the way for 50 different types of cancer to be added to the list of sicknesses covered by a $4.3 billion fund set up to compensate and treat people exposed to the toxic smoke, dust and fumes in the months after the Sept. 11, 2001, terrorist attacks.The

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

The National Health Security Office Working Group (NHSO WG) conducted structured, evidence-based deliberations to generate recommendations for the National Health Security Board on the kidney replacement therapy (KRT) policy. These are the proposed recommendations: To consider defining KRT p

Abstract Disease prioritization for inclusion into Thailand’s population-based screening benefit package Sitaporn Youngkong*, Patsri Srisuwan†, Tanunya Koopitakkajorn*, Pritaporn Kingkaew*, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess*, Kanitta Bundhamcharoen#, Yot Teerawattananon* *He

A Systematic Review of Economic Evaluation Literature in Thailand. Are the Data Good Enough to be Used by Policy-Makers? Yot Teerawattananon1 Steve Russell2 Miranda Mugford3 1 International Health Policy Program, MInistry of Public Health, Nonthaburi, Thailand 2 School of Development Studie

Government use licenses in Thailand: The power of evidence, civil movement and political leadership Suwit Wibulpolprasert1, Vichai Chokevivat2, Cecilia Oh3 and Inthira Yamabhai3* 3Health Intervention and Technology Assessment Program Abstract This paper attempts to describe and analyse t

Government use licenses in Thailand: an assessment of the health and economic impacts Inthira Yamabhai, Adun Mohara, Sripen Tantivess*, Kakanang Chaisiri and Yot Teerawattananon. Health Intervention and Technology Assessment Program (HITAP) Background Between 2006 and 2008, Thailand’s Mi

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac

YOT TEERAWATTANANONa, PRITAPORN KINGKAEWa, TANUNYA KOOPITAKKAJORNa,SITAPORN YOUNGKONGa,b,*, NATTHA TRITASAVITc, PATSRI SRISUWANd and SRIPEN TANTIVESSa aHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand bDepartment of Pharmacy, Faculty of Pharmacy, Mahidol Universi